非小细胞肺癌免疫治疗1例
One Case of Immunotherapy for Non-Small Cell Lung Cancer
DOI: 10.12677/acm.2024.1482354, PDF,   
作者: 潘 登, 张庚艳, 陈 燕, 赵连波：安徽省亳州市蒙城县第一人民医院呼吸与危重症医学科，安徽 亳州
关键词: 非小细胞肺癌；靶向治疗；Non-Small Cell Lung Cancer； Targeted Therapy
摘要: 肺癌(lung cancer, LC)是一种高发病率和高死亡率的原发性癌症类型。其中分为小细胞肺癌(small cell lung cancer, SCLC)和非小细胞肺癌(non-small cell lung cancer, NSCLC)，非小细胞肺癌又分为鳞癌和腺癌。肺癌的危险因素包括吸烟、家族史、辐射暴露和慢性肺病的存在。我们报告了一例非小细胞肺癌患者，其表现为咳嗽咳痰伴胸闷。该患者经胸腔闭式引流后，胸水脱落细胞学检出腺癌细胞，后经全身评估诊断为肺癌(左侧，周围型，腺癌)伴左侧恶性胸腔积液PS评分1分T1bNXM1a IVA期。后家属不同意化疗，胸水基因检测结果示检测出突变位点EGFR 19del。患者遵指南口服奥西替尼，后经复查患者胸部CT好转明显。本病例研究强调了靶向治疗对终末期非小细胞癌治疗的重要性。
Abstract: Lung cancer (LC) is a primary cancer type with high morbidity and mortality. It is divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), and NSCLC is further divided into squamous cell carcinoma and adenocarcinoma. Risk factors for lung cancer include smoking, family history, radiation exposure, and the presence of chronic lung disease. We report a patient with non-small cell lung cancer who presented with cough and phlegm with chest tightness. Adenocarcinoma cells were detected by cytology after pleural fluid shedding after closed thoracic drainage. After a comprehensive examination, the patient was diagnosed with lung cancer (left, peripheral type, adenocarcinoma) with a PS score of 1 and left malignant pleural effusion. The TNM staging was T1bNXM1a, stage IVA. After the family refused chemotherapy, the genetic test of pleural effusion showed a mutation site at EGFR 19del. The patient followed the guidelines and took osimertinib orally. After further examination, the patient’s chest CT showed significant improvement. This case study highlights the importance of targeted therapy in the treatment of end-stage non-small cell carcinoma.
文章引用：潘登, 张庚艳, 陈燕, 赵连波. 非小细胞肺癌免疫治疗1例[J]. 临床医学进展, 2024, 14(8): 1304-1310. https://doi.org/10.12677/acm.2024.1482354

参考文献

[1] Chen, P., Liu, Y., Wen, Y. and Zhou, C. (2022) Non‐small Cell Lung Cancer in China. Cancer Communications, 42, 937-970. [Google Scholar] [CrossRef] [PubMed]
[2] Ramalingam, S. and Belani, C.P. (2007) Recent Advances in Targeted Therapy for Non-Small Cell Lung Cancer. Expert Opinion on Therapeutic Targets, 11, 245-257. [Google Scholar] [CrossRef] [PubMed]
[3] 唐聪聪, 陈艾琪, 杜小萌, 等. 基于CT影像组学在非小细胞肺癌表皮生长因子受体突变中的预测价值[J]. 中国CT和MRI杂志, 2023, 21(10): 67-70.
[4] Workman, S., Jabbour, S.K. and Deek, M.P. (2023) A Narrative Review of Genetic Biomarkers in Non-Small Cell Lung Cancer: An Update and Future Perspectives. AME Medical Journal, 8, Article 6. [Google Scholar] [CrossRef] [PubMed]
[5] Diao, X., Guo, C. and Li, S. (2022) Lymphatic Metastasis in Non‐small Cell Lung Cancer: Recent Discoveries and Novel Therapeutic Targets. Cancer Communications, 42, 1403-1406. [Google Scholar] [CrossRef] [PubMed]
[6] Guo, H., Li, W., Qian, L. and Cui, J. (2021) Clinical Challenges in Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer. Chinese Journal of Cancer Research, 33, 203-215. [Google Scholar] [CrossRef] [PubMed]
[7] McCoach, C.E., Blumenthal, G.M., Zhang, L., Myers, A., Tang, S., Sridhara, R., et al. (2017) Exploratory Analysis of the Association of Depth of Response and Survival in Patients with Metastatic Non-Small-Cell Lung Cancer Treated with a Targeted Therapy or Immunotherapy. Annals of Oncology, 28, 2707-2714. [Google Scholar] [CrossRef] [PubMed]
[8] Miyawaki, T., Naito, T., Yabe, M., et al. (2021) Impact of Cancer Cachexia on Treatment with PD-1/PD-L1 Inhibitors Plus Chemotherapy in Advanced Non-Small-Cell Lung Cancer. Supportive Care in Cancer, 30, 1633-1641.
[9] Zang, X., Qian, C., Ruan, Y., Xie, J., Luo, T., Xu, B., et al. (2019) Higher Maternal Embryonic Leucine Zipper Kinase mRNA Expression Level Is a Poor Prognostic Factor in Non-Small-Cell Lung Carcinoma Patients. Biomarkers in Medicine, 13, 1349-1361. [Google Scholar] [CrossRef] [PubMed]
[10] Zhou, S., Zhang, Z., Zheng, P., Zhao, W. and Han, N. (2017) Microrna-1285-5p Influences the Proliferation and Metastasis of Non-Small-Cell Lung Carcinoma Cells via Downregulating CDH1 and Smad4. Tumor Biology, 39, 1-10. [Google Scholar] [CrossRef] [PubMed]
[11] Furrukh, M., Burney, I.A., Kumar, S., Zahid, K.F. and Al-Moundhri, M. (2013) Improving Outcomes in Advanced Lung Cancer: Maintenance Therapy in Non-Small-Cell Lung Carcinoma. Sultan Qaboos University Medical Journal, 13, 3-18. [Google Scholar] [CrossRef] [PubMed]
[12] Li, S., Wang, A., Wu, Y., He, S., Shuai, W., Zhao, M., et al. (2023) Targeted Therapy for Non‐Small‐Cell Lung Cancer: New Insights into Regulated Cell Death Combined with Immunotherapy. Immunological Reviews, 321, 300-334. [Google Scholar] [CrossRef] [PubMed]
[13] Liu, S., Liu, S.M., Zhong, W. and Wu, Y. (2022) Targeted Therapy in Early Stage Non-Small Cell Lung Cancer. Current Treatment Options in Oncology, 23, 1169-1184. [Google Scholar] [CrossRef] [PubMed]
[14] Devarakonda, S., Govindan, R. and Morgensztern, D. (2020) Mastering the Complex Targeted Therapy for Non-Small Cell Lung Cancer. Cancer Cell, 38, 320-322. [Google Scholar] [CrossRef] [PubMed]
[15] Sa, H., Song, P., Ma, K., Gao, Y., Zhang, L. and Wang, D. (2019) perioperative Targeted Therapy or Immunotherapy in Non-Small-Cell Lung Cancer. OncoTargets and Therapy, 12, 8151-8159. [Google Scholar] [CrossRef] [PubMed]
[16] Rocco, D., Della Gravara, L., Avellino, A., Montesarchio, V. and Battiloro, C. (2018) Immunotherapy as a Targeted Therapy in Non-Small Cell Lung Cancer. Translational Cancer Research, 8, S70-S75. [Google Scholar] [CrossRef] [PubMed]
[17] Tian, X., Gu, T., Lee, M. and Dong, Z. (2022) Challenge and Countermeasures for EGFR Targeted Therapy in Non-Small Cell Lung Cancer. Biochimica et Biophysica Acta (BBA)—Reviews on Cancer, 1877, Article ID: 188645. [Google Scholar] [CrossRef] [PubMed]
[18] Li, K., Cao, X., Ai, B., Xiao, H., Huang, Q., Zhang, Z., et al. (2021) Salvage Surgery Following Downstaging of Advanced Non‐Small Cell Lung Cancer by Targeted Therapy. Thoracic Cancer, 12, 2161-2169. [Google Scholar] [CrossRef] [PubMed]
[19] Imyanitov, E.N., Iyevleva, A.G. and Levchenko, E.V. (2021) Molecular Testing and Targeted Therapy for Non-Small Cell Lung Cancer: Current Status and Perspectives. Critical Reviews in Oncology/Hematology, 157, Article ID: 103194. [Google Scholar] [CrossRef] [PubMed]
[20] Cheng, Y., Zhang, T. and Xu, Q. (2021) Therapeutic Advances in Non‐Small Cell Lung Cancer: Focus on Clinical Development of Targeted Therapy and Immunotherapy. MedComm, 2, 692-729. [Google Scholar] [CrossRef] [PubMed]
[21] Karlsen, E., Kahler, S., Tefay, J., Joseph, S.R. and Simpson, F. (2021) Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review. Cells, 10, Article 1206. [Google Scholar] [CrossRef] [PubMed]
[22] Cai, J., Wei, J.P. and Liu, A.W. (2019) Clinicopathological Analysis of Leptomeningeal Metastasis with Coma in Patients with Non-Small Cell Lung Cancer: A Case Report. Journal of Clinical and Pathological Research, 39, 2579-2586.

为你推荐